Now, it’s worth noting Stock Advisor's total average return is 991% — a market-crushing outperformance compared to 195% for ...

Genetic engineering is moving from the lab bench into clinics, farms, and even family planning decisions, promising to change ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

Editas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) share more than a few similarities despite being at different stages of the biotech lifecycle. Both companies are betting that ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

The problem, Zaaijer explained, is that algorithms used in precision medicine models overwhelming are built on DNA with ...

Editas Medicine announces advancements in in vivo CRISPR gene editing, optimizing costs, and reducing workforce while focusing on hematologic diseases. Editas Medicine, Inc. has announced a strategic ...

For years, Yale researchers David Breslow and Mustafa Khokha have worked together with a similar challenge in their ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Prime Medicine, Inc. (NASDAQ:PRME) stands against the other CRISPR stocks.

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks.

In a major advance, the Food and Drug Administration on Friday approved two gene therapies that target sickle cell disease, one of which is the first commercially available treatment in the United ...

Editas Medicine is a gene-editing biotech, just like CRISPR Therapeutics. Editas has a long way to go before it'll be self-sustaining, and it might not get there. It's also going to be facing down ...